The use of thyroid supplements to augment antidepressant medication

Area of Science:

• Pharmacology
• Neuroscience
• Endocrinology

Background:

• Triiodothyronine (T3) is increasingly recognized for its potential in augmenting antidepressant treatment.
• Existing data, despite methodological limitations, suggest T3's effectiveness across various antidepressant classes.
• Lithium augmentation serves as a benchmark for comparison in treatment-resistant depression.

Purpose of the Study:

• To evaluate the efficacy of triiodothyronine (T3) as an augmentation strategy for antidepressant therapy.
• To compare the efficacy of T3 with lithium in patients who do not respond to standard antidepressants.
• To identify potential predictors for preferential response to T3 augmentation.

Main Methods:

• Review of existing literature documenting the efficacy of T3 augmentation.
• Comparative analysis of studies examining T3 and lithium in antidepressant nonresponders.
• Exploration of biochemical and clinical data for response predictors.

Main Results:

• A significant body of evidence supports T3's efficacy as an augmentation agent.
• One study indicates T3 and lithium possess comparable efficacy in nonresponding patients.
• No definitive biochemical or clinical predictors for T3 response have been identified.

Conclusions:

• Triiodothyronine (T3) is a viable augmentation strategy for antidepressant treatment.
• T3 demonstrates comparable efficacy to lithium in nonresponders, warranting further investigation.
• Optimal dosing and duration of T3 augmentation require additional research.